Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jesse Jaime

Nurse Practitioner, Family Las Cruces, NM Nurse Practitioner

NPI 1801568647 CMS profile 11264549

1250 N Sonoma Ranch Blvd, Las Cruces, NM 88011

Open in the dashboard

General payments

$1,698

70 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Jaime of Las Cruces, NM is reported in the CMS Open Payments database as having received $1,698 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $148 3
2024 General $254 4
2023 General $206 5
2022 General $590 32
2021 General $499 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Jaime
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jesse Jaime were reported at $148. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jesse Jaime Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $499 $124 $35–$379 $132
2022 $590 $141 $44–$430 $149
2023 $206 $154 $49–$476 $160
2024 $254 $165 $51–$504 $164
2025 $148 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $503 17 payments
  2. Bard Peripheral Vascular, Inc. $211 13 payments
  3. Biotronik Inc. $182 6 payments
  4. Janssen Pharmaceuticals, Inc $155 10 payments
  5. AstraZeneca Pharmaceuticals LP $134 3 payments
  6. Nevro Corp. $116 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $109 6 payments
  8. Cardiovascular Systems Inc. $102 5 payments
  9. Philips Electronics North America Corporation $56 1 payment
  10. Novartis Pharmaceuticals Corporation $52 3 payments
  11. Other $77 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,522 66 payments
  2. Education $175 4 payments
Products named General payments · program years 2021–2025
  1. ENDURANT IIS $189 4 payments
  2. Solia $182 6 payments
  3. BioMonitor $182 6 payments
  4. Rivacor $182 6 payments
  5. Edora $182 6 payments
  6. Acticor $182 6 payments
  7. XARELTO $140 9 payments
  8. INTELLIS ADAPTIVESTIM $139 2 payments
  9. HawkOne $136 9 payments
  10. Lutonix Drug Coated Balloon $126 6 payments
  11. Other $755 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

271

Median for Nurse Practitioner: 389

Drug cost

$10,245

Median for Nurse Practitioner: $21,885

Branded share of claims

7.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pentoxifylline Generic 138 $6,432
Cilostazol Generic 93 $2,281
Enoxaparin Sodium Generic 20 $1,311
Clopidogrel Clopidogrel Bisulfate Brand 20 $221

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$22,374

Medicare's payments for the services billed

Medicare patients

155

Average age 75

Services billed

242

63 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 63%
Chronic kidney disease 48%
Ischemic heart disease 39%
Heart failure 30%
COPD 27%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record